GlassScriptPhysician profile
Latoya Mullen
NPI 1053850214
$1,935.26
in general payments reported to CMS, 2019-2025
20 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $316 · 2023: $429 · 2024: $272 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.03 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $250.23 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $161.70 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $127.71 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.52 | 2021-2025 | Trintellix |
| Alkermes, INC. | $107.22 | 2021-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.18 | 2023-2025 | Caplyta |
| Tris Pharma INC | $89.07 | 2021-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $86.17 | 2021-2023 | Gralise |
| Neos Therapeutics, LP | $84.51 | 2022-2024 | Adzenys Xr-Odt |
| Corium, LLC | $49.64 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $47.08 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $36.55 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.91 | 2021 | |
| Neurocrine Biosciences, INC. | $29.15 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.45 | 2021 | |
| Noven Therapeutics, LLC | $20.14 | 2024 | Secuado, Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.92 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.25 | 2022 | |
| Eisai INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.